Related Experiment Videos
[Prostate sarcoma: a report of 14 cases].
Hai-jiao Chen1, Ming Xu, Li Zhang
1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. doctor_chen@sohu.com
Zhonghua Nan Ke Xue = National Journal of Andrology
|October 8, 2005
Summary
Prostate sarcoma is a rare cancer. Early symptoms include dysuria, and diagnosis relies on needle biopsy and immuno-histochemical staining. Treatment involves surgery, chemotherapy, and radiotherapy, but prognosis remains poor.
Area of Science:
- Oncology
- Urology
- Pathology
Context:
- Prostate sarcoma is a rare malignancy, accounting for 3.21% of all prostatic malignant tumors in the study period.
- The average age of affected patients was 39.5 years, with a wide range from 17 to 62.
- Dysuria was the primary presenting symptom in most patients.
Purpose:
- To discuss the diagnosis and effective treatment of prostate sarcoma.
- To analyze clinical data from fourteen prostate sarcoma patients treated between 1991 and 2004.
Summary:
- Pathological analysis revealed various subtypes including leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, and spindle cell sarcoma.
- Immuno-histochemical staining aids in differentiating prostate sarcoma subtypes.
- Staging ranged from Ghavimi Stage I to IV, with most patients in Stage II and IV.
Impact:
- The study highlights that while digital rectal examination (DRE) may suggest prostate sarcoma, needle biopsy is crucial for definitive diagnosis.
- Treatment strategies include surgery, chemotherapy, and radiotherapy, though the overall prognosis for prostate sarcoma is poor.
- The findings underscore the importance of early diagnosis and comprehensive treatment for improving outcomes in prostate sarcoma patients.